Heterodimeric Fc cytokines and uses thereof
US12103954B2 · kind B2 · utility
0Cited by
32References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2024 |
| Grant date | Oct 1, 2024 |
| Priority date | — |
| Expiry date | Feb 20, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.